Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bladder Cancer
- Sponsor
- Mansoura University
- Enrollment
- 198
- Locations
- 1
- Primary Endpoint
- Accuracy of Xpert Bladder Cancer Monitor in monitoring of non muscle invasive bladder cancer by comparing its results to the results of the standard tool of monitoring of bladder cancer (diagnostic cystoscopy)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently used at the site for detecting recurrent bladder cancer.
Investigators
Amr Abdel-Lateif El-Sawy
Principal Investigator
Mansoura University
Eligibility Criteria
Inclusion Criteria
- •The patient shall meet all of the following criteria in order to be considered eligible for enrollment:
- •Patient has been diagnosed with NMIBC within 24 months of enrollment
- •At the time of the enrollment visit, the patient is scheduled for a cystoscopy within the next 6 weeks of enrollment
Exclusion Criteria
- •Patient has had an excision procedure or BCG treatment within six weeks (42 days) before enrollment.
Outcomes
Primary Outcomes
Accuracy of Xpert Bladder Cancer Monitor in monitoring of non muscle invasive bladder cancer by comparing its results to the results of the standard tool of monitoring of bladder cancer (diagnostic cystoscopy)
Time Frame: within 1 month after test assessment
Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy